ABVC BioPharma surges on FDA nod to start lung cancer drug trial

ABVC Biopharma

05/01/2023 14:42

** Drug developer ABVC BioPharma Inc  ABVC.O  surges ~116%
to $1.34, among top pct gainers across U.S. exchanges
    ** Co says FDA has allowed co to proceed with the clinical
study of ABV-1519, which is being studied for the treatment of a
type of lung cancer
    ** FDA has accepted its application for the clinical
investigation of BLEX 404, the primary active ingredient in co's
non-small cell lung cancer drug ABV-1519 - ABVC
    ** The treatment is being co-developed by co's unit and
Rgene Corporation
    ** As a result of the approval, its unit BioKey Inc has
earned a milestone payment of $600,000
    ** Co lost 81.6% last year
 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))